Currently Viewing:
Currently Reading
AJMC® in the Press, April 19, 2019
April 19, 2019 – AJMC Staff
AJMC® in the Press, March 15, 2019
March 15, 2019 – AJMC Staff
Detecting MRD During and After Hematopoietic Stem Cell Transplantation
March 04, 2019 – Laura Joszt
AJMC® in the Press, March 1, 2019
March 01, 2019 – AJMC Staff
Palliative Care, Hospice Improves End-of-Life Care Among Patients With Hematologic Malignancies
February 22, 2019 – Jaime Rosenberg
Measuring the Success of the 7-Day Pledge Program to Avert Postdischarge Hospital Visits
February 03, 2019 – Wallace Stephens
AJMC® in the Press, February 1, 2019
February 01, 2019 – AJMC Staff
FDA Approves Ibrutinib Combination as Frontline Treatment for CLL
January 28, 2019 – Jaime Rosenberg
AJMC® in the Press, January 25, 2019
January 25, 2019 – AJMC Staff

AJMC® in the Press, April 19, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article from The American Journal of Managed Care® (AJMC®) was highlighted by Orthopedics This Week. The article, “Bundled Payments for Joint Replacement Brings Better Outcomes, Lower Costs in NYU Pilot,” covered reports that the 3-year pilot study resulted in the average cost-per-episode dropping by $6708 from the first year of the pilot to the third year, and that NYU’s Department of Orthopaedic Surgery saw reductions in overall length of stay, fewer admissions for follow-up care, and lower readmission rates at the 30-day, 60-day, and 90-day marks.

OBR Oncology’s Wednesday newsfeed included an article from AJMC®’s sister site The Center for Biosimilars®. The article, “Updated ASCO and ASH Guidelines on Managing Anemia Support Safety, Efficacy of Biosimilar ESAs,” covered the updated practice guideline on the use of erythropoiesis-stimulating agents in cancer care, which states that the available literature suggests that biosimilars of epoetin alfa have similar efficacy and safety to reference agents and that biosimilars and their references may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent.

The Center for Biosimilars®’ article “Diverging from US, Canada Approves Biosimilar Rituximab in Both Oncology and Rheumatology Indications” was cited by the Regulatory Affairs Professionals Society. The article reported that last week, Health Canada approved Celltrion and Teva’s biosimilar rituximab, Truxima, for the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up